
Eikon Therapeutics, Inc. (NASDAQ:EIKN – Free Report) – Equities researchers at HC Wainwright lifted their FY2026 earnings estimates for Eikon Therapeutics in a research report issued on Thursday, November 12th. HC Wainwright analyst S. Nik now expects that the company will post earnings of ($7.11) per share for the year, up from their prior estimate of ($7.40). HC Wainwright has a “Buy” rating and a $23.00 price objective on the stock. The consensus estimate for Eikon Therapeutics’ current full-year earnings is ($7.04) per share. HC Wainwright also issued estimates for Eikon Therapeutics’ Q4 2026 earnings at ($1.69) EPS and FY2027 earnings at ($7.50) EPS.
Several other equities analysts have also weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Eikon Therapeutics in a research note on Friday, August 21st. Mizuho upgraded Eikon Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 16th. Wall Street Zen raised Eikon Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings raised Eikon Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday. Finally, Wedbush cut their price objective on Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Eikon Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $24.67.
View Our Latest Report on Eikon Therapeutics
Eikon Therapeutics Stock Performance
NASDAQ:EIKN opened at $5.15 on Monday. Eikon Therapeutics has a 52 week low of $4.95 and a 52 week high of $17.40. The stock’s 50-day moving average price is $7.31 and its 200-day moving average price is $9.99.
Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($1.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15.
Institutional Trading of Eikon Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc acquired a new position in shares of Eikon Therapeutics during the 2nd quarter worth about $28,000. Integrated Wealth Concepts LLC purchased a new position in Eikon Therapeutics in the 2nd quarter valued at about $142,000. Citadel Advisors LLC acquired a new stake in Eikon Therapeutics in the 2nd quarter worth about $170,000. Entropy Technologies LP acquired a new stake in Eikon Therapeutics in the 3rd quarter worth about $125,000. Finally, Deutsche Bank AG acquired a new stake in Eikon Therapeutics in the 2nd quarter worth about $281,000.
Insiders Place Their Bets
In related news, major shareholder Group Iv Gp Lp Column acquired 89,200 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were acquired at an average cost of $11.56 per share, with a total value of $1,031,152.00. Following the completion of the acquisition, the insider directly owned 89,200 shares in the company, valued at approximately $1,031,152. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
About Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets. Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines.
Read More
- Five stocks we like better than Eikon Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
